New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
08:34 EDTNBYNovaBay announces completion of enrollment in Phase 2 BAYnovation trial
NovaBay announced it has completed enrollment of patients in its global Phase 2b viral conjunctivitis trial, BAYnovation. The trial is investigating NovaBay’s Auriclosene -- NVC-422 -- Ophthalmic Solution as a treatment for adenoviral conjunctivitis, a highly contagious, potentially sight-impairing form of “pink eye”. This condition affects millions of people globally and there is currently no approved treatment available anywhere in the world. NovaBay expects to report results from its trial in mid-2014. BAYnovation is a multi-centered, randomized clinical study that has enrolled patients with adenoviral conjunctivitis in the United States, India, Sri Lanka, and Brazil. Patients were enrolled into the study by 54 clinical investigators, including 18 in the US, 19 in India, 6 in Sri Lanka and 11 in Brazil. BAYnovation was designed to evaluate the efficacy of NovaBay’s Auriclosene Ophthalmic Solution in the treatment of adenoviral infection, specifically clearing the associated red eye and reducing lingering effects left by the infection.
News For NBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 25, 2015
09:35 EDTNBYNovaBay to host special shareholder meeting
Subscribe for More Information
September 24, 2015
07:05 EDTNBYNovaBay announces partnership with Alphaeon for Avenova products
ALPHAEON Corporation and NovaBay announced that they have formed a partnership that will add NovaBay's Avenova to the products that ALPHAEON makes available to patients and doctors. Under terms of the agreement, Avenova will now be available for purchase on the ShoutMD Store, the first social commerce store for lifestyle healthcare products. On ShoutMD, member physicians will now be able to learn about Avenova, rate, review and purchase it for their patients.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use